

*B1  
Contd*

6 ring atoms, wherein the heterocyclic group comprises a heteroatom selected from N, O and S, and wherein the carbocyclic or heterocyclic group may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO<sub>2</sub>, (f) CF<sub>3</sub>, (g) C<sub>1-4</sub> alkyl, (h) SCH<sub>3</sub>, (i) NHCOCH<sub>3</sub>, (j) N(R<sup>6</sup>)(R<sup>8</sup>) wherein R<sup>6</sup> and R<sup>8</sup> are the same or different and each represents H or C<sub>1-4</sub> alkyl, (k) OR<sup>10</sup> wherein R<sup>10</sup> represents a saturated or unsaturated C<sub>1-6</sub> straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO<sub>2</sub> and CF<sub>3</sub>, and (l) -OCOR<sup>11</sup> wherein R<sup>11</sup> represents a saturated or unsaturated C<sub>1-6</sub> straight or branched hydrocarbyl group or a phenyl group;

R represents OH, OR<sup>10</sup> or OCOR<sup>11</sup> wherein R<sup>10</sup> and R<sup>11</sup> are as defined above; and R<sup>1</sup> represents H or a C<sub>1-6</sub> straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO<sub>2</sub> and CF<sub>3</sub>;

with the proviso that:

(i) when R<sup>1</sup> is CH<sub>3</sub> and R is OH, then Ar cannot be 4-pyridyl, 4-methylphenyl, 3-nitrophenyl, 3-methoxy-4-ethoxyphenyl, 3-methoxy-4-n-butoxyphenyl, 4-(N,N-dimethylamino)phenyl, 2-hydroxy-3,5-dibromophenyl, 2-hydroxy-5-methylphenyl, 4-chlorophenyl, phenyl, 3-methoxyphenyl, 4-methoxyphenyl, or 3,4-dimethoxyphenyl;


(ii) when R<sup>1</sup> is CH<sub>3</sub> and R is OCOCH<sub>3</sub>, the group, then Ar cannot be phenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 4-(N,N-dimethylamino)phenyl, 3-methoxy-4-acetoxyphenyl, 3,4,5-trimethoxyphenyl, or 2-chlorophenyl;

(iii) when R<sup>1</sup> is phenyl or H and R is OCH<sub>3</sub> or OH, then Ar cannot be 4-methoxyphenyl; and

(iv) when R<sup>1</sup> is CH<sub>3</sub> and R is OCH<sub>3</sub> or OH, then Ar cannot be 4-methoxyphenyl or 3,4-dimethoxyphenyl.

*B2*

48. (Amended) A method of treating cancer in a patient comprising administering to the patient a compound of formula:




*B2  
Cont*

or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents: a substituted or unsubstituted, aromatic or non-aromatic, carbocyclic or heterocyclic group having from 5 to 10 ring atoms or two rings with each ring containing 5 or 6 ring atoms, wherein the heterocyclic group comprises a heteroatom selected from N, O and S, and wherein the carbocyclic or heterocyclic group may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO<sub>2</sub>, (f) CF<sub>3</sub>, (g) C<sub>1-4</sub> alkyl, (h) SCH<sub>3</sub>, (i) NHCOCH<sub>3</sub>, (j) N(R<sup>6</sup>)(R<sup>8</sup>) wherein R<sup>6</sup> and R<sup>8</sup> are the same or different and each represents H or C<sub>1-4</sub> alkyl, (k) OR<sup>10</sup> wherein R<sup>10</sup> represents a saturated or unsaturated C<sub>1-6</sub> straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO<sub>2</sub> and CF<sub>3</sub>, and (l) -OCOR<sup>11</sup> wherein R<sup>11</sup> represents a saturated or unsaturated C<sub>1-6</sub> straight or branched hydrocarbyl group or a phenyl group.

R represents OH, OR<sup>10</sup> or OCOR<sup>11</sup> wherein R<sup>10</sup> and R<sup>11</sup> are as defined above; and R<sup>1</sup> represents H or a C<sub>1-6</sub> straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO<sub>2</sub> and CF<sub>3</sub>.

49. (Amended) A method of treating or preventing neoplasms in a patient comprising administering to the patient a compound of formula:



or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents: a substituted or unsubstituted, aromatic or non-aromatic, carbocyclic or heterocyclic group having from 5 to 10 ring atoms or two rings with each ring containing 5 or 6 ring atoms, wherein the heterocyclic group comprises a heteroatom selected from N, O and S, and wherein the carbocyclic or heterocyclic group may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO<sub>2</sub>, (f) CF<sub>3</sub>, (g) C<sub>1-4</sub> alkyl, (h) SCH<sub>3</sub>, (i) NHCOCH<sub>3</sub>, (j) N(R<sup>6</sup>)(R<sup>8</sup>) wherein R<sup>6</sup> and R<sup>8</sup> are the same or different and each represents H or C<sub>1-4</sub> alkyl, (k) OR<sup>10</sup> wherein R<sup>10</sup> represents a saturated or unsaturated C<sub>1-6</sub> straight or branched hydrocarbyl group which may be

*B<sup>2</sup>*  
*Contd*


unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO<sub>2</sub> and CF<sub>3</sub>, and (I) -OCOR<sup>11</sup> wherein R<sup>11</sup> represents a saturated or unsaturated C<sub>1-6</sub> straight or branched hydrocarbyl group or a phenyl group;

R represents OH, OR<sup>10</sup> or OCOR<sup>11</sup> wherein R<sup>10</sup> and R<sup>11</sup> are as defined above; and  
R<sup>1</sup> represents H or a C<sub>1-6</sub> straight or branched hydrocarbyl group which may be  
unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br,  
F, OMe, NO<sub>2</sub> and CF<sub>3</sub>.

*B<sup>3</sup>*

56. (Amended) A [The] pharmaceutical composition comprising:

(A) a compound of Formula (I):



or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents: a substituted or unsubstituted, aromatic or non-aromatic, carbocyclic or heterocyclic group having from 5 to 10 ring atoms or two rings with each ring containing 5 or 6 ring atoms, wherein the heterocyclic group comprises a heteroatom selected from N, O and S, and wherein the carbocyclic or heterocyclic group may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO<sub>2</sub>, (f) CF<sub>3</sub>, (g) C<sub>1-4</sub> alkyl, (h) SCH<sub>3</sub>, (i) NHCOCH<sub>3</sub>, (j) N(R<sup>6</sup>)(R<sup>8</sup>) wherein R<sup>6</sup> and R<sup>8</sup> are the same or different and each represents H or C<sub>1-4</sub> alkyl, (k) OR<sup>10</sup> wherein R<sup>10</sup> represents a saturated or unsaturated C<sub>1-6</sub> straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO<sub>2</sub> and CF<sub>3</sub>, and (l) -OCOR<sup>11</sup> wherein R<sup>11</sup> represents a saturated or unsaturated C<sub>1-6</sub> straight or branched hydrocarbyl group or a phenyl group;

R represents OH, OR<sup>10</sup> or OCOR<sup>11</sup> wherein R<sup>10</sup> and R<sup>11</sup> are as defined above; and  
R<sup>1</sup> represents H or a C<sub>1-6</sub> straight or branched hydrocarbyl group which may be  
unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br,  
F, OMe, NO<sub>2</sub> and CF<sub>3</sub>; and

(B) one or more antineoplastic agents.

A complete listing of the currently pending claims is provided in Appendix B for the Examiners convenience.